Table 4.

Prevalence of PIM and crude and adjusted analyses of this outcome according to demographic and health variables, type of healthcare system and polypharmacy in elderly patients with Alzheimer's disease. (n = 234).

	Variables	% PIM	Crude analyses prevalence ratio (95% CI)	P valor	Adjusted analyses P (95% CI)	P
	Sex			.467∗		.559∗
1st level	Male	72.0	1.00		1.00
	Female	63.8	0.89 (0.64–1.23)		0.90 (0.65–1.25)
	Age, y			.715∗∗		.754∗∗
	65–74	65.5	1.00		1.00
	75–84	72.6	1.11 (0.74–1.66)		1.12 (0.75–1.67)
	>85	61.7	0.94 (0.61–1.45)		0.95 (0.62–1.47)
	Time since diagnosis, y			.805∗∗		.761∗∗
	<1	55.6	1.00		1.00
	1–2	66.7	1.20 (0.60–2.40)		1.16 (0.56–2.41)
	>2–5	69.0	1.24 (0.63–2.45)		1.20 (0.59–2.47)
	>5	65.3	1.18 (0.60–2.32)		1.17 (0.57–2.48)
	Hypertension			.070∗		.338∗
	No	57.6	1.00		1.00
	Yes	77.1	1.34 (0.98–1.83)		1.18 (0.84–1.64)
2nd level	Depression			<.001∗		.010∗
	No	51.6	1.00		1.00
	Yes	98.7	1.91 (1.40–2.62)		1.57 (1.11–2.20)
	Psychosis			.025∗∗		.288∗
	No	62.3	1.00		1.00
	Yes	100.0	1.05 (1.01–1.10)		1.03 (0.98–1.08)
	Comorbidities (n)			<.001∗∗		.005∗∗
	0–1	31.4	1.00		1.00
	2	72.6	2.31 (1.39–3.85)		2.03 (1.20–3.43)
	3	82.6	2.62 (1.55–4.44)		2.20 (1.27–3.82)
	4 or +	91.1	2.90 (1.76–4.78)		2.35 (1.39–4.02)
	Level of autonomy (0–10)			.929∗∗		.545∗∗
	None (0)	70.0	1.00		1.00
	1–5	65.1	0.93 (0.51–1.71)		0.74 (0.40–1.40)
	6–9	65.8	0.94 (0.53–1.66)		0.76 (0.42–1.38)
	10	66.7	0.95 (0.45–1.99)		0.72 (0.33–1.57)
	Type of health care			.981∗		.531∗
	Public	66.2	1.00		1.00
3rd level	Private and public	66.5	1.00 (0.70–1.44)		0.89 (0.62–1.28)
	Polypharmacy			<.001∗		.158∗
	No (≤4 medications)	46.9	1.00		1.00
	Yes (≥5 medications)	90.6	1.93 (1.40–2.67)		1.38 (0.88–2.17)

CI = confidence interval, PIM = potentially inappropriate medications.

^∗Wald test for heterogeneity.

^∗∗Wald test for linear trend.